News

Patterson Companies, Inc.'s PDCO subsidiary, Patterson Dental Supply, Inc., recently announced a new product, Patterson CarePay+. The product is available to new and existing Eaglesoft practice management software customers.

Patterson CarePay+, which is powered by seamless integration with Wellfit Technologies, Inc., will likely provide dental offices with software solutions for patient financing, dental insurance plans and payment processing.

The latest addition to Patterson Companies’ product portfolio is expected to significantly boost its Dental business unit.

Significance of the Launch

With Wellfit's healthcare financial technology applications, Patterson CarePay+ is expected to provide patients and dental practices with a frictionless payment experience, allowing customization and patient choice.

Per management, patients (both with and without other dental insurance) can now be offered alternative payment options via customizable dental plans, patient financing options and payment processing with the Patterson CarePay+ solution. For dental offices, Patterson CarePay+ can aid in increasing patient retention, improve overall patient care and streamline practice operations.

Industry Prospects

Per a report by Grand View Research, the global dental practice management software market was estimated at $2.6 billion in 2023 and is anticipated to witness a CAGR of approximately 10.2% between 2024 and 2030. Factors like increasing dental visits and the growing adoption of healthcare IT solutions in oral practice procedures are likely to drive the market.

Given the market potential, the latest launch is expected to solidify Patterson Companies’ foothold in the niche space.

Notable Developments

In March, Patterson Dental expanded its Eaglesoft claims processing and insurance services to include Vyne Dental. The collaboration with Vyne Dental will likely ensure rapid resolution of insurance claims and attachments, real-time eligibility checks and electronic remittance advice.

In February, Patterson Companies’ reported its third-quarter fiscal 2024 results, wherein it recorded an uptick in its internal sales driven by dental consumables growth and a year-over-year increase in internal sales of dental consumables (excluding the deflationary impact of certain infection control products).

Price Performance

Patterson Companies’ stock has lost 8.4% over the past year against the industry’s 4% rise and the S&P 500's 23.3% growth.

Image Source: Zacks Investment Research

Zacks Rank & Stocks to Consider

Currently, Patterson Companies carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, Boston Scientific Corporation BSX and Ecolab Inc. ECL.

DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DaVita’s shares have gained 48.4% compared with the industry’s 21.3% rise in the past year.

Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average being 7.5%.

Boston Scientific has gained 46.9% compared with the industry’s 1.9% rise in the past year.

Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.3%.

Ecolab’s shares have rallied 33.3% against the industry’s 9.7% decline in the past year.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

Ecolab Inc. (ECL) : Free Stock Analysis Report

DaVita Inc. (DVA) : Free Stock Analysis Report

Patterson Companies, Inc. (PDCO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.